American Journal of Clinical Dermatology

, Volume 11, Supplement 1, pp 3–9

Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis

  • Srdjan Prodanovich
  • Carlos Ricotti
  • Brad P. Glick
  • Luca Inverardi
  • Craig L. Leonardi
  • Francisco Kerdel
Review Article

DOI: 10.2165/1153413-S0-000000000-00000

Cite this article as:
Prodanovich, S., Ricotti, C., Glick, B.P. et al. AM J Clin Dermatol (2010) 11: 3. doi:10.2165/1153413-S0-000000000-00000

Abstract

Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFα antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound–for example, in detailed comparative studies and economic analyses—is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Srdjan Prodanovich
    • 1
  • Carlos Ricotti
    • 1
  • Brad P. Glick
    • 1
  • Luca Inverardi
    • 1
  • Craig L. Leonardi
    • 1
  • Francisco Kerdel
    • 1
  1. 1.Florida Academic Dermatology CentersMiamiUSA